Core Viewpoint - The company, a leading domestic medical imaging equipment manufacturer, has undergone significant strategic empowerment since Midea Group's acquisition in 2021, focusing on product structure upgrades and marketing reforms to enhance its market position and operational resilience [1][2]. Group 1: Company Performance - In 2024, the company achieved a revenue of 1.524 billion yuan (+23.26%) and a net profit of 157 million yuan (-16.54%), indicating a resilient performance despite industry pressures [1]. - The company has implemented a new round of equity incentive plans in March 2025, emphasizing revenue growth and R&D investment, reflecting confidence in its development [1]. Group 2: Market Position and Product Development - The company remains the domestic leader in the DR segment, with a continuous increase in market share and a focus on high-end imaging equipment such as MR, CT, and DSA [2]. - The introduction of innovative products, including the world's first full-field DR high-end product and a 1.5T superconducting MR, has strengthened the company's competitive position, particularly in secondary and lower-tier medical institutions [2]. Group 3: AI Integration and Future Growth - The AI medical imaging market is projected to reach 8.84 billion yuan in 2024, with a CAGR of nearly 50% until 2028, prompting the company to strategically partner with Alibaba Health to enhance its AI capabilities [3]. - The company's AI initiatives, including the Kunlun AI smart imaging platform and the rapid development of its imaging SaaS platform, have led to significant growth in service coverage, reaching over 7,000 hospitals and serving more than 60 million patients [3]. - Revenue from the company's cloud business, Wanliyun, has grown from 66 million yuan in 2020 to 124 million yuan in 2023, with a CAGR of 23.2%, indicating robust growth potential as AI business matures [3].

证券代码：600055 证券简称：万东医疗 公告编号：临 2025-018 北京万东医疗科技股份有限公司关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 28 日（星期一）14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 21 日（星期一）至 4 月 25 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wdm_ir@wandong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 北京万东医疗科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 22 日发布公司 2024 年度报告，并拟于 2025 年 4 月 26 日发布公司 2025 ...

北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2024 年年度股东大会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 R EUME S Fi YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI AN 致:北京万东医疗科技股份有限公司 在本法律意见书中,本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人资格、会议表决程序、表决结果等所涉及的有关法律问题发 表意见,不对本次股东大会审议的议案内容以及该等议案所表述的事实或数据的 真实性及准确性发表意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完整,所发 北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2024 年年度股东大会的法律意见书 嘉源 ...

证券代码：600055 证券简称：万东医疗 公告编号：2025-016 北京万东医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 4 月 16 日 (二) 股东大会召开的地点：公司本部（北京市朝阳区酒仙桥东路 9 号 院 3 号楼） (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份 情况： | 1、出席会议的股东和代理人人数 | 213 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 326,828,263 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 46.4864 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持 情况等。 会议由公司董事长胡自强先生主持，采取现场及网络相结合的方式投票 表决并形成会议决议，会议的召集、召开及表决符合《 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 根据中国证券监督管理委员会发布的《上市公司股权激励管理办法》 《上市公司信息披露管理办法》等规定的要求，北京万东医疗科技股份有 限公司（以下简称"公司"）对公司2025年股票期权激励计划（以下简称 "激励计划"）采取了充分必要的保密措施，同时对本次激励计划的内幕 信息知情人及激励对象进行了登记。 2025 年 3 月 20 日，公司召开第十届董事会第六次会议，审议通过《关 于<万东医疗 2025 年股票期权激励计划（草案）>及其摘要的议案》《关于< 万东医疗 2025 年股票期权激励计划实施考核管理办法>的议案》及《关于 提请股东大会授权董事会办理 2025 年股票期权激励计划相关事宜的议案》 等相关议案，并于 2025 年 3 月 22 日在上海证券交易所网站披露相关公告。 根据《上市公司股权激励管理办法》的有关规定，公司对内幕信息知情人 及激励对象在激励计划公告前 6 个月内买卖公司股票的情况进行自查，具 体情况如下： 证券代码：600055 证券简称：万东医疗 编号：临 ...

Summary of Conference Call Company and Industry Overview - The conference call discusses the performance of a medical equipment company in 2024, highlighting a revenue growth of approximately 23% year-on-year, which is considered a counter-cyclical growth compared to the overall industry [1] - The company has a significant presence in the private healthcare market and basic medical services, contributing to its revenue increase [1] Key Points and Arguments Revenue and Growth - The company’s overseas revenue, particularly in regions like Central Asia, Latin America, the Middle East, and Africa, accounts for about 80% of its international sales, with expected growth rates of 50-60% over the next three years [2] - The product line for DSA, mobile DR, and other dynamic products constitutes around 20% of the business, with the fastest growth seen in high-end products like MR and CT, achieving over 70% and 50% year-on-year growth respectively [4][5] - The private medical institutions contribute over 40% to the company's revenue, indicating a strong demand for new procurement in this sector [9] Market Trends and Strategies - The company is focusing on high-end DR products and aims to capture more market share through strategic bidding in high-end segments [7] - The "宇宙换星" project is expected to enhance procurement demand, with anticipated larger funding in the second wave compared to the first [8] - The company plans to expand its product categories and local operations in key areas to sustain high overseas growth rates [2][15] Product Development and AI Integration - The company is integrating AI functionalities across its product lines to enhance diagnostic efficiency and image quality [23][24] - There is a focus on developing core components for MR products, with expectations for significant advancements by 2027 [34] Financial Outlook - The company anticipates maintaining a mid-to-high single-digit growth rate in the industry over the next two to three years, with a potential increase in revenue driven by high-end product launches [11][29] - The gross margin is expected to stabilize and gradually improve as high-end product lines are introduced [28][29] Challenges and Market Dynamics - The company acknowledges the impact of centralized procurement on sales, which is a growing trend in the medical equipment sector [12][11] - There are concerns about the slowing growth in the private market, with expectations for public hospital procurement to improve gradually [9] Additional Important Insights - The company is actively pursuing investment and acquisition opportunities to ensure efficient use of its cash reserves [10] - The strategic focus includes building localized capabilities in 20 countries to enhance service delivery and product offerings [14] - The company is also addressing the challenges posed by geopolitical factors and tariffs in its overseas operations, ensuring a stable market presence in favorable regions [35] This summary encapsulates the key discussions and insights from the conference call, providing a comprehensive overview of the company's performance, strategies, and market outlook.

Core Viewpoint - The announcement details the verification and public disclosure of the incentive plan for stock options at Beijing Wandong Medical Technology Co., Ltd, ensuring compliance with relevant regulations and confirming the eligibility of the proposed incentive recipients [1][2]. Disclosure Situation - The company published the list of incentive recipients on March 22, 2025, on the Shanghai Stock Exchange website and other designated media, with an internal public notice period from March 28 to April 8, 2025, during which no objections were received [1]. Supervisory Board Verification Opinion - The supervisory board verified the qualifications of the proposed incentive recipients, confirming that all individuals listed meet the requirements set forth in the Company Law, Securities Law, and relevant regulations [2]. - The basic information of the proposed incentive recipients is accurate, with no instances of falsehood or significant misrepresentation [3]. - None of the proposed recipients fall under the disqualifying conditions outlined in Article 8 of the Management Measures, such as being deemed inappropriate by the stock exchange or regulatory authorities within the last 12 months [4]. - The proposed incentive recipients do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares, ensuring compliance with the incentive plan's criteria [4].

证券代码：600055 证券简称：万东医疗 编号：临 2025-015 北京万东医疗科技股份有限公司监事会 关于股票期权激励计划激励对象名单 的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 公司于2025年3月22日在上海证券交易所网站和指定披露媒体上发布 《万东医疗2025年股票期权激励计划激励对象名单》，并在公司内部对上述 激励对象的姓名与职务进行公示，公示时间为2025年3月28日至2025年4月8 日。截至公示期满，未收到与本次激励对象有关的任何异议。 二、监事会核查意见 公司监事会对本次拟激励对象的名单、身份证件、与公司（含分子公 司，下同）签订的劳动合同、担任职务等情况进行了核查。根据《管理办 法》《公司章程》及公司对拟授予的激励对象名单及职务的公示情况，并结 合监事会的核查结果，监事会发表核查意见如下： 1、列入本次激励计划激励对象名单的人员均具备《公司法》《证券法》 等有关法律、法规、规范性文件和《公司章程》规定的任职资格。 2、本次拟激励对象的基本情况属实，不存在虚假、故意隐瞒或致 ...

2025 年 4 月 万东医疗 2024 年度股东大会会议资料 万东医疗 2024 年度股东大会会议资料 北京万东医疗科技股份有限公司 北京万东医疗科技股份有限公司 2024 年度股东大会会议议程 2024 年度股东大会会议资料 现场会议时间：2025 年 4 月 16 日下午 13:00 时。 交易系统投票平台投票时间：2025 年 4 月 16 日交易时间段。 互联网投票平台投票时间：2025 年 4 月 16 日 9:15-15:00。 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式。 现场会议地点：北京市朝阳区酒仙桥东路 9 号院 3 号楼。 参加会议人员：2025 年 4 月 7 日下午收市后，在中国证券登记结算有 限公司上海分公司登记在册的本公司股东及股东代表；公司董事、监事及 高级管理人员；律师。 会议登记时间：2025 年 4 月 8 日上午 9：00-11：30，下午 13：00－17： 00。 会议议程： 一、主持人宣布股东到会情况 股东大会召集人：公司董事会 二、审议会议议案、按审议事项的顺序逐项投票表决 议案 11：关于提请股东大会授权董事会办理 2025 年 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of over 15% in the next six months [4]. Core Insights - The company's performance meets expectations, with a projected revenue growth of 23% and a non-GAAP net profit growth of 5% for 2024. The profit margin is primarily impacted by a decline in gross margin [1][3]. - The company has launched a stock option incentive plan for 2025, with ambitious revenue growth targets of 27.5%, 62%, and 120% for the years 2025 to 2027, reflecting strong long-term confidence [1][11]. - The domestic market share for CT, MR, and DSA products remains low, suggesting significant growth potential as the company enhances its high-end product lineup and expands into overseas markets [1][15]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 1.524 billion yuan, a 23% increase year-on-year, while the net profit attributable to shareholders was 157 million yuan, a 17% decrease [2][3]. - The fourth quarter of 2024 saw revenues of 431 million yuan, a 39% increase, while the net profit decreased by 39% to 42 million yuan [3]. Product Performance - The company achieved significant growth in CT and MR product sales, with MR sales increasing by 93% and CT sales by 90% in 2024. Revenue from MR grew by 75% and CT by 55% [8][9]. - The company is focusing on high-end product development, with new products like the 3.0T MR and 64-slice CT expected to drive future growth [9][10]. Market Outlook - The report anticipates continued improvement in industry bidding activities and the implementation of new equipment update policies, which should support revenue growth [1][15]. - The company is expected to maintain a strong growth trajectory in overseas markets, with a projected revenue increase of 68% from international sales in 2024 [3][9]. Research and Development - The company is increasing its R&D investment, with a projected R&D expense of 165 million yuan in 2025, reflecting a commitment to innovation and product development [10][11]. - The gross margin is expected to decline to 36.6% in 2024, primarily due to changes in product mix, with lower-margin products gaining a larger share of revenue [10][17]. Future Projections - Revenue forecasts for 2025, 2026, and 2027 are 1.947 billion yuan, 2.496 billion yuan, and 3.322 billion yuan, respectively, with year-on-year growth rates of 28%, 28%, and 33% [15][17]. - The projected net profit for the same years is expected to be 191 million yuan, 240 million yuan, and 318 million yuan, with growth rates of 21%, 26%, and 32% [15][17].